← All trials
NCT06760078
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Jul 1, 2026
- First posted
- Jan 6, 2025
- Last posted
- Jan 7, 2025
- Enrollment
- 532
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Government of ChinaCollaborator
- Linyi People's HospitalCollaborator
- Peking UniversityCollaborator
- Jiaozuo Tumor HospitalCollaborator
- Suzhou First People's HospitalCollaborator
- Central South UniversityCollaborator
- Capital Medical UniversityOfficial
- The First People's Hospital of Qujing, Yunnan ProvinceCollaborator
- The People's Hospital of Liaoning ProvinceCollaborator
- Wuzhou Red Cross HospitalCollaborator
- Capital Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.